To target mutant RAS in the GTP-bound RAS(ON) state for cancer treatment, Revolution Medicines Inc. has developed a platform in which binding and inhibition occur through small molecule-driven formation of a high-affinity ternary complex (tri-complex) between the target protein, a small molecule and a chaperone such as cyclophilin A.
Jacobio Pharmaceuticals Co. Ltd. has synthesized new protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Nanchang Helioeast Technology Co. Ltd. has identified new oxa-azaspiro compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
Jiangsu Simcere Pharmaceutical Co. Ltd. has divulged bicyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Immuneering Corp. has submitted an IND application to the FDA to support a phase I/IIa trial of IMM-1-104, an oral once-daily small molecule in development for the treatment of advanced RAS-mutant solid tumors.
Researchers from Italfarmaco SpA presented a new class of highly selective histone deacetylase 6 (HDAC6) inhibitors as potential candidates for the treatment of several pathologies, such as autoimmune disorders, neurodegenerative diseases, and cancer.
Analyzing RNA from blood platelets detected up to 18 different cancers, at early as well as late stages, with a specificity of 99% in asymptomatic controls. The specificity for symptomatic controls, including those who had inflammatory diseases, cardiovascular disease, or benign tumors, was 78%.
RSS
